If you run DMPK, your day is volume: hundreds of injections a study, discovery screens by the plate, and PK support that everything downstream waits on, much of it at a CRO. The manual load is integration, curve review, and acceptance calls, one after another. EI Flow automates that stack to review by exception, so bioanalysis, screening, metabolite ID, and modeling all move without the review queue as the ceiling.
LC-MS / LC-MS/MS / MRM
Bioanalysis and quantitation. Run acceptance, quantitation review, metabolite tracking, stability, and impurity monitoring across every injection, with your integration and acceptance decisions applied at every site, including CROs. The highest-throughput method in DMPK, so consistency across sites matters most here.
HRMS / QTOF
Metabolite identification and MIST. Captures your metabolite calls and standardizes the threshold decisions the safety story rests on, compressing slow structure-elucidation review.
ADME screening (Caco-2, PAMPA, metabolic stability, protein binding, solubility).
The discovery ADME panel. Plate-based, SOP-defined readouts where EI Flow automates the curve fits, ratios, and acceptance calls, and flags the anomalies worth your time.
CYP and transporter assays (DDI).
CYP inhibition and induction, P-gp and BCRP efflux. Deterministic, high-volume plate readouts; EI Flow signs the passing plates and flags time-dependent inhibition and efflux anomalies.
PBPK / PopPK modeling
Simulation QC and sign-off. The same governed, signed review EI Flow brings to wet-lab data, applied to model runs, flagging out-of-expectation outputs so a modeled result carries the same audit trail as a measured one.
Radiolabeled ADME / AMS
Mass balance and routes of elimination. Low volume, high regulatory stakes; EI Flow's value is exception-flagging and audit-ready documentation of the definitive data an NDA or BLA rests on.
CMC
If you run DMPK, your day is volume: hundreds of injections a study, discovery screens by the plate, and PK support that everything downstream waits on, much of it at a CRO. The manual load is integration, curve review, and acceptance calls, one after another. EI Flow automates that stack to review by exception, so bioanalysis, screening, metabolite ID, and modeling all move without the review queue as the ceiling.
LC-MS / LC-MS/MS / MRM
Bioanalysis and quantitation. Run acceptance, quantitation review, metabolite tracking, stability, and impurity monitoring across every injection, with your integration and acceptance decisions applied at every site, including CROs. The highest-throughput method in DMPK, so consistency across sites matters most here.
HRMS / QTOF
Metabolite identification and MIST. Captures your metabolite calls and standardizes the threshold decisions the safety story rests on, compressing slow structure-elucidation review.
ADME screening (Caco-2, PAMPA, metabolic stability, protein binding, solubility).
The discovery ADME panel. Plate-based, SOP-defined readouts where EI Flow automates the curve fits, ratios, and acceptance calls, and flags the anomalies worth your time.
CYP and transporter assays (DDI).
CYP inhibition and induction, P-gp and BCRP efflux. Deterministic, high-volume plate readouts; EI Flow signs the passing plates and flags time-dependent inhibition and efflux anomalies.
PBPK / PopPK modeling
Simulation QC and sign-off. The same governed, signed review EI Flow brings to wet-lab data, applied to model runs, flagging out-of-expectation outputs so a modeled result carries the same audit trail as a measured one.
Radiolabeled ADME / AMS
Mass balance and routes of elimination. Low volume, high regulatory stakes; EI Flow's value is exception-flagging and audit-ready documentation of the definitive data an NDA or BLA rests on.
QC
If you run DMPK, your day is volume: hundreds of injections a study, discovery screens by the plate, and PK support that everything downstream waits on, much of it at a CRO. The manual load is integration, curve review, and acceptance calls, one after another. EI Flow automates that stack to review by exception, so bioanalysis, screening, metabolite ID, and modeling all move without the review queue as the ceiling.
LC-MS / LC-MS/MS / MRM
Bioanalysis and quantitation. Run acceptance, quantitation review, metabolite tracking, stability, and impurity monitoring across every injection, with your integration and acceptance decisions applied at every site, including CROs. The highest-throughput method in DMPK, so consistency across sites matters most here.
HRMS / QTOF
Metabolite identification and MIST. Captures your metabolite calls and standardizes the threshold decisions the safety story rests on, compressing slow structure-elucidation review.
ADME screening (Caco-2, PAMPA, metabolic stability, protein binding, solubility).
The discovery ADME panel. Plate-based, SOP-defined readouts where EI Flow automates the curve fits, ratios, and acceptance calls, and flags the anomalies worth your time.
CYP and transporter assays (DDI).
CYP inhibition and induction, P-gp and BCRP efflux. Deterministic, high-volume plate readouts; EI Flow signs the passing plates and flags time-dependent inhibition and efflux anomalies.
PBPK / PopPK modeling
Simulation QC and sign-off. The same governed, signed review EI Flow brings to wet-lab data, applied to model runs, flagging out-of-expectation outputs so a modeled result carries the same audit trail as a measured one.
Radiolabeled ADME / AMS
Mass balance and routes of elimination. Low volume, high regulatory stakes; EI Flow's value is exception-flagging and audit-ready documentation of the definitive data an NDA or BLA rests on.